Journals / Retina-Vitreus / 2013 / Cilt: 21 - Sayı: 4

A comparison of short-term effects of ıntravitreal triamcinolone acetonide and bevacizumab on retinal vascular caliber in patients with diabetic macular edema

Diyabetik maküler ödemi olan hastalarda intravitreal triamsinolon asetonid ve bevacizumabın retinal damar çapı üzerine kısa dönem etkilerinin karşılaştırılması

Pages
259–264
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: In short-term, intravitreal triamcinolone acetonide led to more significant changes than intravitreal bevacizumab in retinal vascular caliber.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To compare the retinal vascular caliber changes in diabetic macular edema patients receiving intravitreal triamcinolone acetonide and bevacizumab.
📊
Key Findings & Data:Materials and Methods: Retinal vascular caliber of 42 patients with diabetic macular edema aged between 41-78 were measured before, 1 week and 4 weeks after the intravitreal injection. 21 (50.0%) patients received 2 mg/0.05 ml intravitreal triamcinolone acetonide and 21 (50.0%) patients received 1.25 mg/0.05 ml intravitreal bevacizumab.
💡
Conclusion & Impact:Conclusions: In short-term, intravitreal triamcinolone acetonide led to more significant changes than intravitreal bevacizumab in retinal vascular caliber.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To compare the retinal vascular caliber changes in diabetic macular edema patients receiving intravitreal triamcinolone acetonide and bevacizumab. Materials and Methods: Retinal vascular caliber of 42 patients with diabetic macular edema aged between 41-78 were measured before, 1 week and 4 weeks after the intravitreal injection. 21 (50.0%) patients received 2 mg/0.05 ml intravitreal triamcinolone acetonide and 21 (50.0%) patients received 1.25 mg/0.05 ml intravitreal bevacizumab. Retinal vascular caliber assessment was performed manually on retinal nerve fiber layer imaging mode scan by using semi-automated program of Spectralis optical coher- ence tomography. Statistical analyses of differences between retinal vascular caliber were determined using repeated measures of analysis of variance and Bonferroni adjustment. Results: Mean retinal arteriolar diameter of healthy control group, triamcinolone group, and bevacizumab group before the in- jection was 88.55±11.29, 87.19±10.00 and 91.67±16.69 &#956;m, respectively. Mean retinal venular diameter of healthy control group, triamcinolone group, and bevacizumab group before the injection was 127.00±16.91, 130.38±24.01 and 132.52±18.74 &#956;m, respec- tively. In triamcinolone group, there was statistically significant decline in retinal arteriolar and venular diameter during the study period (p values were 0.047 and <0.001, respectively). In bevacizumab group, retinal venular diameter was significantly decreased (p<0.001) but there was no significant change in retinal arteriolar diameter during the study period (p=0.209). Conclusions: In short-term, intravitreal triamcinolone acetonide led to more significant changes than intravitreal bevacizumab in retinal vascular caliber.

Özet

Amaç: Diyabetik maküla ödemi nedeniyle intravitreal triamsinolon asetonid ve bevacizumab uygulanan hastalarda retina damar çapı değişikliklerinin karşılaştırılması. Gereç ve Yöntem: Yaşları 41-78 arası değişen 42 diyabetik maküla ödemi olan hastanın intravitreal enjeksiyondan önce, enjek- siyondan bir hafta ve dört hafta sonra retina damar çapı ölçümleri gerçekleştirildi. Hastaların 21’ine (%50.0) 2 mg/0.05 ml intra- vitreal triamsinolon asetonid ve 21’ine (%50.0) 1.25mg/0.05 ml intravitreal bevacizumab uygulandı. Retinal damar çapı ölçümleri, Spectralis optik koherens tomografi cihazındaki retina sinir lifi ölçüm modu görüntüsü kullanılarak cihazda yüklü olan yarı oto- matik program yardımı ile manuel olarak yapıldı. Retina damar çapı değişiklikleri arasındaki farkın istatistiksel analizi ilişkili örneklem tek yönlü varyans analizi ve Bonferroni düzeltmesi ile değerlendirildi. Bulgular: Sağlıklı kontrol grubu ile triamsinolon ve bevacizumab gruplarının enjeksiyon öncesi ortalama retinal arteriyol çapları sırasıyla 88.55±11.29, 87.19±10.00 ve 91.67±16.69 μm idi. Sağlıklı kontrol grubu ile triamsinolon ve bevacizumab gruplarının enjeksiyon öncesi ortalama retinal venül çapları sırasıyla 127.00±16.91, 130.38±24.01 ve 132.52±18.74 μm idi. Triamsinolon gru- bunda çalışma süresince istatistiksel olarak anlamlı düzeyde retina arteriyol ve venüllerinde daralma gözlendi (p değerleri sıra- sıyla 0.047 ve <0.001). Çalışma süresince bevacizumab grubunda, retina venüllerinde istatistiksel olarak anlamlı daralma olurken (p<0.001), retina arteriyollerinde istatistiksel olarak anlamlı değişiklik saptanmadı (p=0.209). Sonuç: Kısa dönem değerlendirmelerinde, retina damar çaplarında intravitreal olarak uygulanan triamsinolon asetonid, bevaci- zumabdan daha belirgin değişikliklere neden olmaktadır.

🔖

Cite This Article

ULAŞ, F., DOĞAN, Ü., ÇELİK, F., ŞAHİN, S., ÇELEBİ, S. (2013). A comparison of short-term effects of ıntravitreal triamcinolone acetonide and bevacizumab on retinal vascular caliber in patients with diabetic macular edema. Retina-Vitreus, Cilt: 21 - Sayı: 4, 259–264. https://ajindex.com/articles/305085

References (15)

  1. Klein R, Knudtson MD, Lee KE, et al. The Wisconsin Epi- demiologic Study of Diabetic Retinopathy XXIII: the twenty- five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 2009;116:497-503
  2. Nguyen QD, Shah SM, Van Anden E, et al. Supplemental oxy- gen improves diabetic macular edema: a pilot study. Invest Ophthalmol Vis Sci 2004;45:617-24
  3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopa- thy and other retinal disorders. N Engl J Med 1994;331:1480-7
  4. Bresnick GH. Diabetic maculopathy. A critical review highlighting diffuse macular edema. Ophthalmology 1983;90:1301-17
  5. Lee CM,Olk RJ. Modified grid laser photocoagulation for dif- fuse diabetic macular edema. Long-term visual results. Oph- thalmology 1991;98:1594-602
  6. Koss MJ, Naser H, Sener A, et al. Combination therapy in diabetic macular oedema and retinal vein occlusion--past and present. Acta Ophthalmol 2012;90:580-9
  7. Wong TY, Klein R, Klein BE, et al. Retinal microvascular abnormalities and their relationship with hypertension, cardiovascular disease, and mortality. Surv Ophthalmol 2001;46:59-80
  8. Cheung N, Mitchell P,Wong TY. Diabetic retinopathy. Lancet 2010;376:124-36
  9. Wong TY. Retinal vessel diameter as a clinical predictor of diabetic retinopathy progression: time to take out the measur- ing tape. Arch Ophthalmol 2011;129:95-6
  10. Stefansson E, Landers MB, 3rd,Wolbarsht ML. Oxygenation and vasodilatation in relation to diabetic and other prolifera- tive retinopathies. Ophthalmic Surg 1983;14:209-26
  11. Ding J, Ikram MK, Cheung CY, et al. Retinal vascular calibre as a predictor of incidence and progression of diabetic reti- nopathy. Clin Exp Optom 2012;95:290-6
  12. Edelman JL, Lutz D,Castro MR. Corticosteroids inhibit VEGF-induced vascular leakage in a rabbit model of blood- retinal and blood-aqueous barrier breakdown. Exp Eye Res 2005;80:249-58
  13. Vinten M, Larsen M, Lund-Andersen H, et al. Short-term ef- fects of intravitreal triamcinolone on retinal vascular leakage and trunk vessel diameters in diabetic macular oedema. Acta Ophthalmol Scand 2007;85:21-6
  14. Marshall J. The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol 2005;32:S43-7
  15. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal tri- amcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmo